337 related articles for article (PubMed ID: 26070269)
1. ERβ1 inversely correlates with PTEN/PI3K/AKT pathway and predicts a favorable prognosis in triple-negative breast cancer.
Wang J; Zhang C; Chen K; Tang H; Tang J; Song C; Xie X
Breast Cancer Res Treat; 2015 Jul; 152(2):255-69. PubMed ID: 26070269
[TBL] [Abstract][Full Text] [Related]
2. Insulin growth factor receptor-1 expression and loss of PTEN protein predict early recurrence in triple-negative breast cancer.
Iqbal J; Thike AA; Cheok PY; Tse GM; Tan PH
Histopathology; 2012 Oct; 61(4):652-9. PubMed ID: 22759273
[TBL] [Abstract][Full Text] [Related]
3. INPP4B and PTEN Loss Leads to PI-3,4-P2 Accumulation and Inhibition of PI3K in TNBC.
Reed DE; Shokat KM
Mol Cancer Res; 2017 Jun; 15(6):765-775. PubMed ID: 28196852
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological significance of PTEN loss and the phosphoinositide 3-kinase/Akt pathway in sporadic colorectal neoplasms: is PTEN loss predictor of local recurrence?
Colakoglu T; Yildirim S; Kayaselcuk F; Nursal TZ; Ezer A; Noyan T; Karakayali H; Haberal M
Am J Surg; 2008 Jun; 195(6):719-25. PubMed ID: 18440486
[TBL] [Abstract][Full Text] [Related]
5. Expression of NY-ESO-1 in Triple-Negative Breast Cancer Is Associated with Tumor-Infiltrating Lymphocytes and a Good Prognosis.
Lee HJ; Kim JY; Song IH; Park IA; Yu JH; Gong G
Oncology; 2015; 89(6):337-44. PubMed ID: 26413775
[TBL] [Abstract][Full Text] [Related]
6. The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome.
Panigrahi AR; Pinder SE; Chan SY; Paish EC; Robertson JF; Ellis IO
J Pathol; 2004 Sep; 204(1):93-100. PubMed ID: 15307142
[TBL] [Abstract][Full Text] [Related]
7. Dysregulated PI3K/Akt/PTEN pathway is a marker of a short disease-free survival in node-negative breast carcinoma.
Capodanno A; Camerini A; Orlandini C; Baldini E; Resta ML; Bevilacqua G; Collecchi P
Hum Pathol; 2009 Oct; 40(10):1408-17. PubMed ID: 19428048
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
Choi JE; Kang SH; Lee SJ; Bae YK
Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
[TBL] [Abstract][Full Text] [Related]
9. Divergence of P53, PTEN, PI3K, Akt and mTOR expression in tonsillar cancer.
Chun SH; Jung CK; Won HS; Kang JH; Kim YS; Kim MS
Head Neck; 2015 May; 37(5):636-43. PubMed ID: 24616007
[TBL] [Abstract][Full Text] [Related]
10. The presence and impact of estrogen metabolism on the biology of triple-negative breast cancer.
McNamara KM; Oguro S; Omata F; Kikuchi K; Guestini F; Suzuki K; Yang Y; Abe E; Hirakawa H; Brown KA; Takanori I; Ohuchi N; Sasano H
Breast Cancer Res Treat; 2017 Jan; 161(2):213-227. PubMed ID: 27848152
[TBL] [Abstract][Full Text] [Related]
11. Activated PI3K/AKT and MAPK pathways are potential good prognostic markers in node-positive, triple-negative breast cancer.
Hashimoto K; Tsuda H; Koizumi F; Shimizu C; Yonemori K; Ando M; Kodaira M; Yunokawa M; Fujiwara Y; Tamura K
Ann Oncol; 2014 Oct; 25(10):1973-1979. PubMed ID: 25009009
[TBL] [Abstract][Full Text] [Related]
12. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
[TBL] [Abstract][Full Text] [Related]
13. Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.
Cossu-Rocca P; Orrù S; Muroni MR; Sanges F; Sotgiu G; Ena S; Pira G; Murgia L; Manca A; Uras MG; Sarobba MG; Urru S; De Miglio MR
PLoS One; 2015; 10(11):e0141763. PubMed ID: 26540293
[TBL] [Abstract][Full Text] [Related]
14. Loss of PTEN expression is associated with aggressive behavior and poor prognosis in Middle Eastern triple-negative breast cancer.
Beg S; Siraj AK; Prabhakaran S; Jehan Z; Ajarim D; Al-Dayel F; Tulbah A; Al-Kuraya KS
Breast Cancer Res Treat; 2015 Jun; 151(3):541-53. PubMed ID: 25981902
[TBL] [Abstract][Full Text] [Related]
15. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
[TBL] [Abstract][Full Text] [Related]
16. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy.
Pantuck AJ; Seligson DB; Klatte T; Yu H; Leppert JT; Moore L; O'Toole T; Gibbons J; Belldegrun AS; Figlin RA
Cancer; 2007 Jun; 109(11):2257-67. PubMed ID: 17440983
[TBL] [Abstract][Full Text] [Related]
17. Difference in expression of EGFR, pAkt, and PTEN between oropharyngeal and oral cavity squamous cell carcinoma.
Won HS; Jung CK; Chun SH; Kang JH; Kim YS; Sun DI; Kim MS
Oral Oncol; 2012 Oct; 48(10):985-990. PubMed ID: 22682934
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer.
Aleskandarany MA; Rakha EA; Ahmed MA; Powe DG; Ellis IO; Green AR
Breast Cancer Res Treat; 2011 Jun; 127(2):407-16. PubMed ID: 20617378
[TBL] [Abstract][Full Text] [Related]
19. Statin induces inhibition of triple negative breast cancer (TNBC) cells via PI3K pathway.
Park YH; Jung HH; Ahn JS; Im YH
Biochem Biophys Res Commun; 2013 Sep; 439(2):275-9. PubMed ID: 23973711
[TBL] [Abstract][Full Text] [Related]
20. Loss of PTEN in high grade advanced stage triple negative breast ductal cancers in African American women.
Khan F; Esnakula A; Ricks-Santi LJ; Zafar R; Kanaan Y; Naab T
Pathol Res Pract; 2018 May; 214(5):673-678. PubMed ID: 29653745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
